EMT Cancer Research Results

EMT, Epithelial-Mesenchymal Transition: Click to Expand ⟱
Source:
Type:
Biological process in which epithelial cells lose their cell polarity and cell-cell adhesion properties and gain mesenchymal traits, such as increased motility and invasiveness. This process is pivotal during embryogenesis and wound healing. Hh signaling pathway is able to regulate the EMT. Snail, E-cadherin and N-cadherin, key components of EMT; EMT-related factors, E-cadherin, N-cadherin, vimentin; The hallmark of EMT is the upregulation of N-cadherin followed by the downregulation of E-cadherin.
EMT is regulated by various signaling pathways, including TGF-β, Wnt, Notch, and Hedgehog pathways. Transcription factors such as Snail, Slug, Twist, and ZEB play critical roles in repressing epithelial markers (like E-cadherin) and promoting mesenchymal markers (like N-cadherin and vimentin).
EMT is associated with increased tumor aggressiveness, enhanced migratory and invasive capabilities, and resistance to apoptosis.


Scientific Papers found: Click to Expand⟱
6441- SAO,    Sandalwood Album Oil as a Botanical Therapeutic in Dermatology
- Review, PSA, NA
*Inflam↓, *eff↑, *5LO↓, *DPPH↓, *hepatoP↑, *ROS↓, *PGE2↓, *IL1β↓, *IL17↓, *PDE4↓, *tyrosinase↓, *AntiFungal↑, angioG↓, TumCG↓, DNAdam↑, *Snail↑, *Twist↑, *Vim↑, *EMT↓, *toxicity↓,
4485- Se,    Selenium stimulates the antitumour immunity: Insights to future research
- Review, NA, NA
*antiOx↑, chemoPv↑, ROS↑, Imm↑, selenoP↑, *IL2↑, *IL4↑, *TNF-α↓, *TGF-β↓, *EMT↓, Risk↓, *GPx↑, *TrxR↑,
1135- Selenate,    Selenate induces epithelial-mesenchymal transition in a colorectal carcinoma cell line by AKT activation
- in-vitro, CRC, DLD1
EMT↑, Akt↑, Twist↑, Vim↑, E-cadherin↓,
3198- SFN,    Sulforaphane and TRAIL induce a synergistic elimination of advanced prostate cancer stem-like cells
- in-vitro, Pca, NA
Nanog↓, SOX2↓, E-cadherin↓, Snail↓, VEGFR2↓, Diff↓, TumCMig↓, EMT↓, CXCR4↓, NOTCH1↓, ALDH1A1↓, CSCs↓, eff↑,
1136- SFN,    Sulforaphane inhibits epithelial-mesenchymal transition by activating extracellular signal-regulated kinase 5 in lung cancer cells
- in-vitro, Lung, NA - in-vivo, NA, NA
TumCMig↓, E-cadherin↑, ZO-1↑, N-cadherin↓, Snail↓, ERK5↑, EMT↓,
1014- SFN,    Sulforaphane Modulates Cell Migration and Expression of β-Catenin and Epithelial Mesenchymal Transition Markers in Breast Cancer Cells
- in-vitro, BC, MDA-MB-231
Zeb1↓, Apoptosis↑, Fibronectin↓, CLDN1↓, β-catenin/ZEB1↓, EMT↓,
110- SFN,    Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway
- in-vivo, PC, NA
HH↓, Smo↓, Gli1↓, GLI2↓, Shh↓, VEGF↓, PDGFRA↓, EMT↓, Zeb1↓, Bcl-2↓, XIAP↓, E-cadherin↑, OCT4↓, Nanog↓, TumCG↑,
2448- SFN,    Sulforaphane and bladder cancer: a potential novel antitumor compound
- Review, Bladder, NA
Apoptosis↑, TumCG↓, TumCI↓, TumMeta↓, glucoNG↓, ChemoSen↑, TumCCA↑, Casp3↑, Casp7↑, cl‑PARP↑, survivin↓, EGFR↓, HER2/EBBR2↓, ATP↓, Glycolysis↓, mt-OXPHOS↓, AKT1↓, HK2↓, Hif1a↓, ROS↑, NRF2↑, EMT↓, COX2↓, MMP2↓, MMP9↓, Zeb1↓, Snail↓, HDAC↓, HATs↓, MMP↓, Cyt‑c↓, Shh↓, Smo↓, Gli1↓, BioAv↝, BioAv↝, Dose↝,
1466- SFN,    Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway
- vitro+vivo, Thyroid, FTC-133
TumCP↓, TumCCA↑, Apoptosis↑, TumCMig↓, TumCI↓, EMT↓, Slug↓, Twist↓, MMP2↓, MMP9↓, TumCG↓, p‑Akt↓, P21↑, ERK↑, p38↑, ROS↑, *toxicity∅, MMP↓, eff↓,
1462- SFN,    Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells
- in-vitro, Bladder, T24/HTB-9
EMT↓, TumCI↓, TumCMig↓, E-cadherin↑, Zeb1↓, Snail↓, COX2↝, MMP2↝, MMP9↝,
1434- SFN,  GEM,    Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity
- in-vitro, CCA, HuCCT1 - in-vitro, CCA, HuH28 - in-vivo, NA, NA
HDAC↓, ac‑H3↑, ChemoSen↑, tumCV↓, TumCP↓, TumCCA↑, Apoptosis↑, cl‑Casp3↑, TumCI↓, VEGF↓, VEGFR2↓, Hif1a↓, eNOS↓, EMT?, TumCG↓, Ki-67↓, TUNEL↑, P21↑, p‑Chk2↑, CDC25↓, BAX↑, *ROS↓, NQO1?,
1730- SFN,    Sulforaphane: An emergent anti-cancer stem cell agent
- Review, Var, NA
BioAv↓, BioAv↑, GSTA1↑, P450↓, TumCCA↑, HDAC↓, P21↑, p27↑, DNMT1↓, DNMT3A↓, cycD1/CCND1↑, DNAdam↑, BAX↑, Cyt‑c↑, Apoptosis↑, ROS↑, AIF↑, CDK1↑, Casp3↑, Casp8↑, Casp9↑, NRF2↑, NF-kB↓, TNF-α↓, IL1β↓, CSCs↓, CD133↓, CD44↓, ALDH↓, Nanog↓, OCT4↓, hTERT/TERT↓, MMP2↓, EMT↓, ALDH1A1↓, Wnt↓, NOTCH↓, ChemoSen↑, *Ki-67↓, *HDAC3↓, *HDAC↓,
3301- SIL,    Critical review of therapeutic potential of silymarin in cancer: A bioactive polyphenolic flavonoid
- Review, Var, NA
Inflam↓, TumCCA↑, Apoptosis↓, TumMeta↓, TumCG↓, angioG↓, chemoP↑, radioP↑, p‑ERK↓, p‑p38↓, p‑JNK↓, P53↑, Bcl-2↓, Bcl-xL↓, TGF-β↓, MMP2↓, MMP9↓, E-cadherin↑, Wnt↓, Vim↓, VEGF↓, IL6↓, STAT3↓, *ROS↓, IL1β↓, PGE2↓, CDK1↓, CycB/CCNB1↓, survivin↓, Mcl-1↓, Casp3↑, Casp9↑, cMyc↓, COX2↓, Hif1a↓, CXCR4↓, CSCs↓, EMT↓, N-cadherin↓, PCNA↓, cycD1/CCND1↓, ROS↑, eff↑, eff↑, eff↑, HER2/EBBR2↓,
3296- SIL,    Silibinin induces oral cancer cell apoptosis and reactive oxygen species generation by activating the JNK/c-Jun pathway
- in-vitro, Oral, Ca9-22 - in-vivo, Oral, YD10B
TumCP↓, TumCCA↑, ROS↑, SOD1↓, SOD2↓, *JNK↑, toxicity?, TumCMig↓, TumCI↓, N-cadherin↓, Vim↓, E-cadherin↑, EMT↓, P53↑, cl‑Casp3↑, cl‑PARP↑, BAX↑, Bcl-2↓, SOD↓,
3288- SIL,    Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations
- Review, Var, NA
Inflam↓, lipid-P↓, TumMeta↓, angioG↓, chemoP↑, EMT↓, HDAC↓, HATs↑, MMPs↓, uPA↓, PI3K↓, Akt↓, VEGF↓, CD31↓, Hif1a↓, VEGFR2↓, Raf↓, MEK↓, ERK↓, BIM↓, BAX↑, Bcl-2↓, Bcl-xL↓, Casp↑, MAPK↓, P53↑, LC3II↑, mTOR↓, YAP/TEAD↓, *BioAv↓, MMP↓, Cyt‑c↑, PCNA↓, cMyc↓, cycD1/CCND1↓, β-catenin/ZEB1↓, survivin↓, APAF1↑, Casp3↑, MDSCs↓, IL10↓, IL2↑, IFN-γ↑, hepatoP↑, cardioP↑, GSH↑, neuroP↑,
3282- SIL,    Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions
- Review, NA, NA
hepatoP↑, AntiCan↑, TumCMig↓, Hif1a↓, selectivity↑, toxicity∅, *antiOx↑, *Inflam↓, TumCCA↑, P21↑, CDK4↓, NF-kB↓, ERK↓, PSA↓, TumCG↓, p27↑, COX2↓, IL1↓, VEGF↓, IGFBP3↑, AR↓, STAT3↓, Telomerase↓, Cyt‑c↑, Casp↑, eff↝, HDAC↓, HATs↑, Zeb1↓, E-cadherin↑, miR-203↑, NHE1↓, MMP2↓, MMP9↓, PGE2↓, Vim↓, Wnt↓, angioG↓, VEGF↓, *TIMP1↓, EMT↓, TGF-β↓, CD44↓, EGFR↓, PDGF↓, *IL8↓, SREBP1↓, MMP↓, ATP↓, uPA↓, PD-L1↓, NOTCH↓, *SIRT1↑, SIRT1↓, CA↓, Ca+2↑, chemoP↑, cardioP↑, Dose↝, Half-Life↝, BioAv↓, BioAv↓, BioAv↓, toxicity↝, Half-Life↓, ROS↓, FAK↓,
1127- SIL,    Silibinin suppresses epithelial–mesenchymal transition in human non-small cell lung cancer cells by restraining RHBDD1
- in-vitro, Lung, A549
TumCP↓, TumCMig↓, TumCI↓, EMT↓, RHBDD1↓,
2359- SK,    Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery
- in-vivo, Liver, NA
TumCG↓, PKM2↓, EMT↓, TGF-β↓, Glycolysis↓, lactateProd↓, ATP↓,
2197- SK,    Shikonin derivatives for cancer prevention and therapy
- Review, Var, NA
ROS↑, Ca+2↑, BAX↑, Bcl-2↓, MMP9↓, NF-kB↓, PKM2↓, Hif1a↓, NRF2↓, P53↑, DNMT1↓, MDR1↓, COX2↓, VEGF↓, EMT↓, MMP7↓, MMP13↓, uPA↓, RIP1↑, RIP3↑, Casp3↑, Casp7↑, Casp9↑, P21↓, DFF45↓, TRAIL↑, PTEN↑, mTOR↓, AR↓, FAK↓, Src↓, Myc↓, RadioS↑,
2196- SK,    Research progress in mechanism of anticancer action of shikonin targeting reactive oxygen species
- Review, Var, NA
*ALAT↓, *AST↓, *Inflam?, *EMT↑, ROS?, TrxR1↓, PERK↑, eIF2α↑, ATF4↑, CHOP↑, IRE1↑, JNK↑, eff↝, DR5↑, Glycolysis↓, PKM2↓, ChemoSen↑, GPx4↓, HO-1↑,
3048- SK,    Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, 4T1 - in-vitro, Nor, MCF12A - in-vivo, NA, NA
tumCV↓, selectivity↑, EMT↓, TumCMig↓, TumCI↓, E-cadherin↑, N-cadherin↓, Vim↓, Snail↓, β-catenin/ZEB1↓, GSK‐3β↑,
5075- SSE,    Sodium selenite inhibits proliferation and metastasis through ROS‐mediated NF‐κB signaling in renal cell carcinoma
- vitro+vivo, RCC, 786-O
TumCP↓, TumCMig↓, Apoptosis↑, ROS↑, NF-kB↓, eff↓, E-cadherin↑, cl‑Casp3↑, VEGF↓, MMP9↓, EMT↓, MMP↓, mtDam↑, BAX↑, Bcl-2↓,
1575- statins,  Citrate,    Inhibition of Lung Cancer Growth: ATP Citrate Lyase Knockdown and Statin Treatment Leads to Dual Blockade of Mitogen-Activated Protein Kinase (MAPK) and Phosphatidylinositol-3-Kinase (PI3K)/AKT Pathways
- in-vitro, NSCLC, A549
eff↑, HMG-CoA↓, eff↑, AntiTum↑, EGFR↓, eff↑, ROS↑, EMT↓, E-cadherin↑, MUC1↑, p‑ACLY↓, p‑Akt↓, eff↑,
6436- T4O,    Terpinen-4-ol suppresses proliferation and motility of cutaneous squamous cell carcinoma cells by enhancing calpain-2 expression
- in-vitro, Melanoma, A431
TumCP↓, TumCMig↓, TumCI↓, Apoptosis↑, EMT↓, AntiTum↑, cal2↑, cl‑β-catenin/ZEB1↑, cl‑Casp12↑, Bcl-2↓, cycD1/CCND1↓, CDK2↓, BAX↑, TumCCA↑, selectivity↑, N-cadherin↓, E-cadherin↑, Ki-67↓, PCNA↑,
1138- TQ,    Thymoquinone inhibits epithelial-mesenchymal transition in prostate cancer cells by negatively regulating the TGF-β/Smad2/3 signaling pathway
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
TumMeta↓, EMT↓, E-cadherin↑, Vim↓, Slug↓, TGF-β↓, SMAD2↓, SMAD3↓,
2084- TQ,    Thymoquinone, as an anticancer molecule: from basic research to clinical investigation
- Review, Var, NA
*ROS↓, *chemoPv↑, ROS↑, ROS⇅, MUC4↓, selectivity↑, AR↓, cycD1/CCND1↓, Bcl-2↓, Bcl-xL↓, survivin↓, Mcl-1↓, VEGF↓, cl‑PARP↑, ROS↑, HSP70/HSPA5↑, P53↑, miR-34a↑, Rac1↓, TumCCA↑, NOTCH↓, NF-kB↓, IκB↓, p‑p65↓, IAP1↓, IAP2↑, XIAP↓, TNF-α↓, COX2↓, Inflam↓, α-tubulin↓, Twist↓, EMT↓, mTOR↓, PI3K↓, Akt↓, BioAv↓, ChemoSen↑, BioAv↑, PTEN↑, chemoPv↑, RadioS↑, *Half-Life↝, *BioAv↝,
1929- TQ,    Thymoquinone Suppresses the Proliferation, Migration and Invasiveness through Regulating ROS, Autophagic Flux and miR-877-5p in Human Bladder Carcinoma Cells
- in-vitro, Bladder, 5637 - in-vitro, Bladder, T24/HTB-9
tumCV↓, TumCP↓, TumCI↓, Casp↑, ROS↑, PD-L1↓, EMT↓, MMP↓, eff↓,
3407- TQ,    Thymoquinone and its pharmacological perspective: A review
- Review, NA, NA
*antiOx↑, *ROS↓, *GSTs↑, *GSR↑, *GSH↑, *RenoP↑, *IL1β↓, *TNF-α↓, *MMP13↓, *COX2↓, *PGE2↓, *radioP↑, Twist↓, EMT↓, NF-kB↓, p‑PI3K↓, p‑Akt↓, p‑GSK‐3β↓, DNMT1↓, HDAC↓,
3397- TQ,    Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer
- Review, CRC, NA
ChemoSen↑, *Half-Life↝, *BioAv↝, *antiOx↑, *Inflam↓, *hepatoP↑, TumCP↓, TumCCA↑, Apoptosis↑, angioG↑, selectivity↑, JNK↑, p38↑, p‑NF-kB↑, ERK↓, PI3K↓, PTEN↑, Akt↓, mTOR↓, EMT↓, Twist↓, E-cadherin↓, ROS⇅, *Catalase↑, *SOD↑, *GSTA1↑, *GPx↑, *PGE2↓, *IL1β↓, *COX2↓, *MMP13↓, MMPs↓, TumMeta↓, VEGF↓, STAT3↓, BAX↑, Bcl-2↑, Casp9↑, Casp7↑, Casp3↑, cl‑PARP↑, survivin↓, cMyc↓, cycD1/CCND1↓, p27↑, P21↑, GSK‐3β↓, β-catenin/ZEB1↓, chemoP↑,
3422- TQ,    Thymoquinone, as a Novel Therapeutic Candidate of Cancers
- Review, Var, NA
selectivity↑, P53↑, PTEN↑, NF-kB↓, PPARγ↓, cMyc↓, Casp↑, *BioAv↓, BioAv↝, eff↑, survivin↓, Bcl-xL↓, Bcl-2↓, Akt↓, BAX↑, cl‑PARP↑, CXCR4↓, MMP9↓, VEGFR2↓, Ki-67↓, COX2↓, JAK2↓, cSrc↓, Apoptosis↑, p‑STAT3↓, cycD1/CCND1↓, Casp3↑, Casp7↑, Casp9↑, N-cadherin↓, Vim↓, Twist↓, E-cadherin↑, ChemoSen↑, eff↑, EMT↓, ROS↑, DNMT1↓, eff↑, EZH2↓, hepatoP↑, Zeb1↓, RadioS↑, HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, *NAD↑, *SIRT1↑, SIRT1↓, *Inflam↓, *CRP↓, *TNF-α↓, *IL6↓, *IL1β↓, *eff↑, *MDA↓, *NO↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, PI3K↓, mTOR↓,
3431- TQ,    PI3K-AKT Pathway Modulation by Thymoquinone Limits Tumor Growth and Glycolytic Metabolism in Colorectal Cancer
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW48
Glycolysis↓, Warburg↓, HK2↓, ATP↓, NADPH↓, PI3K↓, Akt↓, TumCP↓, E-cadherin↑, N-cadherin↓, Hif1a↓, PKM2↓, GlucoseCon↓, lactateProd↓, EMT↓,
3423- TQ,    Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics
- Review, Var, NA
AntiCan↑, Inflam↓, hepatoP↑, RenoP↑, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, ROS↑, P53↑, PTEN↑, P21↑, p27↑, BRCA1↑, PI3K↓, Akt↓, MAPK↓, ERK↓, p‑ERK↓, MMPs↓, FAK↓, Twist↓, Zeb1↓, EMT↓, TumMeta↓, angioG↓, VEGF↓, HDAC↓, Maspin↑, SIRT1↑, DNMT1↓, DNMT3A↓, HDAC1↓, HDAC4↓,
3571- TQ,    The Role of Thymoquinone in Inflammatory Response in Chronic Diseases
- Review, Var, NA - Review, Stroke, NA
*BioAv↓, *BioAv↑, *Inflam↓, *antiOx↑, *ROS↓, *GSH↑, *GSTs↑, *MPO↓, *NF-kB↓, *COX2↓, *IL1β↓, *TNF-α↓, *IFN-γ↓, *IL6↓, *cardioP↑, *lipid-P↓, *TAC↑, *RenoP↑, Apoptosis↑, TumCCA↑, TumCP↓, TumCMig↓, angioG↓, TNF-α↓, NF-kB↓, ROS↑, EMT↓, *Aβ↓, *p‑tau↓, *BACE↓, *TLR2↓, *TLR4↓, *MyD88↓, *IRF3↓, *eff↑, eff↑, DNAdam↑, *iNOS↓,
5911- TV,    Thymol Isolated from Thymus vulgaris L. Inhibits Colorectal Cancer Cell Growth and Metastasis by Suppressing the Wnt/β-Catenin Pathway
- vitro+vivo, CRC, NA
TumCP↓, Apoptosis↑, TumVol↓, Bax:Bcl2↑, EMT↓, TumCI↓, TumMeta↓, Wnt/(β-catenin)↓,
1139- UA,    Ursolic acid inhibits epithelial-mesenchymal transition by suppressing the expression of astrocyte-elevated gene-1 in human nonsmall cell lung cancer A549 cells
- in-vitro, Lung, A549
TumMeta↓, AEG1↓, E-cadherin↑, N-cadherin↓, Vim↓, EMT↓,
4856- Uro,    Study on the biological mechanism of urolithin a on nasopharyngeal carcinoma in vitro
- in-vitro, NPC, CNE1 - in-vitro, NPC, CNE2
Apoptosis↑, MMP↓, ROS↑, E-cadherin↑, BAX↑, cl‑Casp3↑, PARP↑, MMP2↓, MMP9↓, N-cadherin↓, Vim↓, Snail↓, eff↓, TumCP↓, TumCMig↓, TumCI↓, EMT↓,
4838- Uro,    The Therapeutic Potential of Urolithin A for Cancer Treatment and Prevention
- Review, Var, NA
BioAv↑, Inflam↓, IL6↓, IL1β↓, NOS2↓, p53 Wildtype↑, MDM2↑, Snail↓, E-cadherin↑, N-cadherin↓, Vim↓, NF-kB↓, mTOR↓, p‑Akt↓, selectivity↑, EMT↓,
4844- Uro,    Urolithin A Inhibits Epithelial–Mesenchymal Transition in Lung Cancer Cells via P53-Mdm2-Snail Pathway
- in-vitro, Lung, A549 - in-vitro, Lung, H460
TumCMig↓, TumCI↓, EMT↓, Snail↓, MDM2↑, P53↑, E-cadherin↑, N-cadherin↓, Vim↓,
633- VitC,    Diverse antitumor effects of ascorbic acid on cancer cells and the tumor microenvironment
- Analysis, NA, NA
Fenton↑, ROS↑, EMT↓, DNAdam↑, PARP↑, NAD↓, ATP↓, Apoptosis↑,
1217- VitC,    High-dose vitamin C suppresses the invasion and metastasis of breast cancer cells via inhibiting epithelial-mesenchymal transition
- in-vitro, BC, Bcap37 - in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
TumCMig↓, E-cadherin↑, Vim↓, EMT↓,
4618- VitD3,    Vitamin D sensitizes cervical cancer to radiation-induced apoptosis by inhibiting autophagy through degradation of Ambra1
- in-vivo, Cerv, NA
Risk↓, RadioS↑, Apoptosis↑, EMT↝,
2366- VitD3,    Vitamin D3 decreases glycolysis and invasiveness, and increases cellular stiffness in breast cancer cells
- in-vitro, BC, MCF7
Glycolysis↓, tumCV↓, Apoptosis↑, mTOR↓, AMPK↑, EMT↓, E-cadherin↑, F-actin↑, Vim↓,
1816- VitK2,    Role of Vitamin K in Selected Malignant Neoplasms in Women
- Review, Var, NA
TumCP↓, TumMeta↓, TumAuto↑, Apoptosis↑, Apoptosis↑, Casp3↑, Casp7↑, ROS↑, AR↓, EMT↓, Wnt↓, MMP↓, Cyt‑c↑, NF-kB↓, cycD1/CCND1↓, TumCCA↓,
1821- VitK3,    Menadione (Vitamin K3) induces apoptosis of human oral cancer cells and reduces their metastatic potential by modulating the expression of epithelial to mesenchymal transition markers and inhibiting migration
- in-vitro, Oral, NA - in-vitro, Nor, HEK293 - in-vitro, Nor, HaCaT
selectivity↑, TumCD↓, BAX↑, P53↑, Bcl-2↓, p65↓, E-cadherin↑, EMT↓, Vim↓, Fibronectin↓, TumCG↓, TumCMig↓,
1820- VitK3,    Vitamin K3 (menadione) suppresses epithelial-mesenchymal-transition and Wnt signaling pathway in human colorectal cancer cells
- in-vitro, CRC, SW480 - in-vitro, CRC, SW-620
selectivity↑, TumCI↓, TumCMig↓, EMT↓, E-cadherin↑, ZO-1↑, N-cadherin↓, Vim↓, Zeb1↓, MMP2↓, MMP9↓, TOPflash↓, β-catenin/ZEB1↓, p300↓, cycD1/CCND1↓, TumCCA↑,
1222- Z,    Zinc regulates primary ovarian tumor growth and metastasis through the epithelial to mesenchymal transition
- in-vitro, Ovarian, NA
EMT↑, TumCMig↑, TumCI↑, ERK↑, Akt↑,

Showing Research Papers: 251 to 296 of 296
Prev Page 6 of 6

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 296

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1)

Fenton↑, 1,   GPx4↓, 1,   GSH↑, 1,   GSTA1↑, 1,   HO-1↑, 1,   lipid-P↓, 1,   NQO1?, 1,   NRF2↓, 1,   NRF2↑, 2,   mt-OXPHOS↓, 1,   ROS?, 1,   ROS↓, 1,   ROS↑, 18,   ROS⇅, 2,   selenoP↑, 1,   SOD↓, 1,   SOD1↓, 1,   SOD2↓, 1,   TrxR1↓, 1,  

Mitochondria & Bioenergetics(tgid=3)

AIF↑, 1,   ATP↓, 5,   CDC25↓, 1,   MEK↓, 1,   MMP↓, 8,   mtDam↑, 1,   Raf↓, 1,   XIAP↓, 2,  

Core Metabolism/Glycolysis(tgid=4)

p‑ACLY↓, 1,   AKT1↓, 1,   AMPK↑, 1,   cMyc↓, 4,   glucoNG↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 5,   HK2↓, 2,   HMG-CoA↓, 1,   lactateProd↓, 2,   NAD↓, 1,   NADPH↓, 1,   PKM2↓, 4,   PPARγ↓, 1,   SIRT1↓, 2,   SIRT1↑, 1,   SREBP1↓, 1,   Warburg↓, 1,  

Cell Death(tgid=5)

Akt↓, 6,   Akt↑, 2,   p‑Akt↓, 4,   APAF1↑, 1,   Apoptosis↓, 1,   Apoptosis↑, 17,   Bak↑, 1,   BAX↑, 12,   Bax:Bcl2↑, 1,   Bcl-2↓, 11,   Bcl-2↑, 1,   Bcl-xL↓, 5,   BIM↓, 1,   Casp↑, 4,   cl‑Casp12↑, 1,   Casp3↑, 8,   cl‑Casp3↑, 4,   Casp7↑, 5,   Casp8↑, 1,   Casp9↑, 5,   p‑Chk2↑, 1,   Cyt‑c↓, 1,   Cyt‑c↑, 4,   DR5↑, 1,   hTERT/TERT↓, 1,   IAP1↓, 1,   IAP2↑, 1,   JNK↑, 2,   p‑JNK↓, 1,   MAPK↓, 2,   Mcl-1↓, 2,   MDM2↑, 2,   Myc↓, 1,   p27↑, 4,   p38↑, 2,   p‑p38↓, 1,   RIP1↑, 1,   survivin↓, 6,   Telomerase↓, 1,   TRAIL↑, 1,   TumCD↓, 1,   TUNEL↑, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction(tgid=6)

cSrc↓, 1,   HER2/EBBR2↓, 2,  

Transcription & Epigenetics(tgid=7)

EZH2↓, 1,   ac‑H3↑, 1,   HATs↓, 1,   HATs↑, 2,   tumCV↓, 4,  

Protein Folding & ER Stress(tgid=8)

CHOP↑, 1,   eIF2α↑, 1,   HSP70/HSPA5↑, 1,   IRE1↑, 1,   PERK↑, 1,  

Autophagy & Lysosomes(tgid=9)

LC3II↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10)

BRCA1↑, 1,   DFF45↓, 1,   DNAdam↑, 4,   DNMT1↓, 5,   DNMT3A↓, 2,   P53↑, 9,   p53 Wildtype↑, 1,   PARP↑, 2,   cl‑PARP↑, 5,   PCNA↓, 2,   PCNA↑, 1,  

Cell Cycle & Senescence(tgid=11)

CDK1↓, 1,   CDK1↑, 1,   CDK2↓, 1,   CDK4↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 8,   cycD1/CCND1↑, 1,   P21↓, 1,   P21↑, 6,   TumCCA↓, 1,   TumCCA↑, 12,  

Proliferation, Differentiation & Cell State(tgid=12)

ALDH↓, 1,   ALDH1A1↓, 2,   CD133↓, 1,   CD44↓, 2,   CSCs↓, 3,   Diff↓, 1,   EMT?, 1,   EMT↓, 39,   EMT↑, 2,   EMT↝, 1,   ERK↓, 4,   ERK↑, 2,   p‑ERK↓, 2,   ERK5↑, 1,   Gli1↓, 2,   GSK‐3β↓, 1,   GSK‐3β↑, 1,   p‑GSK‐3β↓, 1,   HDAC↓, 8,   HDAC1↓, 2,   HDAC2↓, 1,   HDAC3↓, 1,   HDAC4↓, 1,   HH↓, 1,   IGFBP3↑, 1,   miR-34a↑, 1,   mTOR↓, 7,   Nanog↓, 3,   NOTCH↓, 3,   NOTCH1↓, 1,   OCT4↓, 2,   p300↓, 1,   PDGFRA↓, 1,   PI3K↓, 6,   p‑PI3K↓, 1,   PTEN↑, 5,   Shh↓, 2,   Smo↓, 2,   SOX2↓, 1,   Src↓, 1,   STAT3↓, 3,   p‑STAT3↓, 1,   TOPflash↓, 1,   TumCG↓, 8,   TumCG↑, 1,   Wnt↓, 4,   Wnt/(β-catenin)↓, 1,  

Migration(tgid=13)

AEG1↓, 1,   CA↓, 1,   Ca+2↑, 2,   cal2↑, 1,   CD31↓, 1,   CLDN1↓, 1,   E-cadherin↓, 3,   E-cadherin↑, 21,   F-actin↑, 1,   FAK↓, 3,   Fibronectin↓, 2,   GLI2↓, 1,   Ki-67↓, 3,   miR-203↑, 1,   MMP13↓, 1,   MMP2↓, 7,   MMP2↝, 1,   MMP7↓, 1,   MMP9↓, 9,   MMP9↝, 1,   MMPs↓, 3,   MUC1↑, 1,   MUC4↓, 1,   N-cadherin↓, 12,   PDGF↓, 1,   Rac1↓, 1,   RHBDD1↓, 1,   RIP3↑, 1,   Slug↓, 2,   SMAD2↓, 1,   SMAD3↓, 1,   Snail↓, 8,   TGF-β↓, 4,   TumCI↓, 13,   TumCI↑, 1,   TumCMig↓, 16,   TumCMig↑, 1,   TumCP↓, 13,   TumMeta↓, 9,   Twist↓, 6,   Twist↑, 1,   uPA↓, 3,   Vim↓, 14,   Vim↑, 1,   Zeb1↓, 8,   ZO-1↑, 2,   α-tubulin↓, 1,   β-catenin/ZEB1↓, 5,   cl‑β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature(tgid=14)

angioG↓, 6,   angioG↑, 1,   ATF4↑, 1,   EGFR↓, 3,   eNOS↓, 1,   Hif1a↓, 7,   VEGF↓, 11,   VEGFR2↓, 4,  

Barriers & Transport(tgid=15)

NHE1↓, 1,  

Immune & Inflammatory Signaling(tgid=16)

COX2↓, 6,   COX2↝, 1,   CXCR4↓, 3,   IFN-γ↑, 1,   IL1↓, 1,   IL10↓, 1,   IL1β↓, 3,   IL2↑, 1,   IL6↓, 2,   Imm↑, 1,   Inflam↓, 5,   IκB↓, 1,   JAK2↓, 1,   MDSCs↓, 1,   NF-kB↓, 10,   p‑NF-kB↑, 1,   p65↓, 1,   p‑p65↓, 1,   PD-L1↓, 2,   PGE2↓, 2,   PSA↓, 1,   TNF-α↓, 3,  

Hormonal & Nuclear Receptors(tgid=20)

AR↓, 4,  

Drug Metabolism & Resistance(tgid=21)

BioAv↓, 5,   BioAv↑, 3,   BioAv↝, 3,   ChemoSen↑, 7,   Dose↝, 2,   eff↓, 4,   eff↑, 12,   eff↝, 2,   Half-Life↓, 1,   Half-Life↝, 1,   MDR1↓, 1,   P450↓, 1,   RadioS↑, 4,   selectivity↑, 9,  

Clinical Biomarkers(tgid=22)

AR↓, 4,   BRCA1↑, 1,   EGFR↓, 3,   EZH2↓, 1,   HER2/EBBR2↓, 2,   hTERT/TERT↓, 1,   IL6↓, 2,   Ki-67↓, 3,   Maspin↑, 1,   Myc↓, 1,   NOS2↓, 1,   PD-L1↓, 2,   PSA↓, 1,  

Functional Outcomes(tgid=23)

AntiCan↑, 2,   AntiTum↑, 2,   cardioP↑, 2,   chemoP↑, 4,   chemoPv↑, 2,   hepatoP↑, 4,   neuroP↑, 1,   radioP↑, 1,   RenoP↑, 1,   Risk↓, 2,   toxicity?, 1,   toxicity↝, 1,   toxicity∅, 1,   TumVol↓, 1,  
Total Targets: 293

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1)

antiOx↑, 5,   Catalase↑, 2,   DPPH↓, 1,   GPx↑, 3,   GSH↑, 3,   GSR↑, 1,   GSTA1↑, 1,   GSTs↑, 2,   lipid-P↓, 1,   MDA↓, 1,   MPO↓, 1,   ROS↓, 6,   SOD↑, 2,   TAC↑, 1,   TrxR↑, 1,  

Core Metabolism/Glycolysis(tgid=4)

ALAT↓, 1,   NAD↑, 1,   SIRT1↑, 2,  

Cell Death(tgid=5)

iNOS↓, 1,   JNK↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12)

EMT↓, 2,   EMT↑, 1,   HDAC↓, 1,   HDAC3↓, 1,   tyrosinase↓, 1,  

Migration(tgid=13)

5LO↓, 1,   Ki-67↓, 1,   MMP13↓, 2,   Snail↑, 1,   TGF-β↓, 1,   TIMP1↓, 1,   Twist↑, 1,   Vim↑, 1,  

Angiogenesis & Vasculature(tgid=14)

NO↓, 1,  

Immune & Inflammatory Signaling(tgid=16)

COX2↓, 3,   CRP↓, 1,   IFN-γ↓, 1,   IL17↓, 1,   IL1β↓, 5,   IL2↑, 1,   IL4↑, 1,   IL6↓, 2,   IL8↓, 1,   Inflam?, 1,   Inflam↓, 5,   MyD88↓, 1,   NF-kB↓, 1,   PGE2↓, 3,   TLR2↓, 1,   TLR4↓, 1,   TNF-α↓, 4,  

Synaptic & Neurotransmission(tgid=18)

p‑tau↓, 1,  

Protein Aggregation(tgid=19)

Aβ↓, 1,   BACE↓, 1,  

Drug Metabolism & Resistance(tgid=21)

BioAv↓, 3,   BioAv↑, 1,   BioAv↝, 2,   eff↑, 3,   Half-Life↝, 2,  

Clinical Biomarkers(tgid=22)

ALAT↓, 1,   AST↓, 1,   CRP↓, 1,   IL6↓, 2,   Ki-67↓, 1,  

Functional Outcomes(tgid=23)

cardioP↑, 1,   chemoPv↑, 1,   hepatoP↑, 2,   PDE4↓, 1,   radioP↑, 1,   RenoP↑, 2,   toxicity↓, 1,   toxicity∅, 1,  

Infection & Microbiome(tgid=24)

AntiFungal↑, 1,   IRF3↓, 1,  
Total Targets: 74

Scientific Paper Hit Count for: EMT, Epithelial-Mesenchymal Transition
19 Curcumin
16 Resveratrol
15 Quercetin
12 Honokiol
10 Sulforaphane (mainly Broccoli)
9 Ashwagandha(Withaferin A)
9 EGCG (Epigallocatechin Gallate)
9 Thymoquinone
8 Fisetin
6 Astragalus
6 Berberine
6 Luteolin
6 Metformin
6 Piperine
6 Rosmarinic acid
5 Apigenin (mainly Parsley)
5 Betulinic acid
5 Chrysin
5 Eugenol
5 Silymarin (Milk Thistle) silibinin
4 Alpha-Lipoic-Acid
4 Baicalein
4 Propolis -bee glue
4 Chlorogenic acid
4 Pterostilbene
4 Shikonin
3 Artemisinin
3 Atorvastatin
3 Cyclopamine
3 salinomycin
3 Genistein (soy isoflavone)
3 Emodin
3 Ferulic acid
3 HydroxyTyrosol
3 Lycopene
3 Nimbolide
3 Piperlongumine
3 Urolithin
2 Anethole/trans-Anethole
2 Cisplatin
2 Astaxanthin
2 Beta-Caryophyllene
2 brusatol
2 Capsaicin
2 Cannabidiol
2 Celecoxib
2 Centella asiatica / Gotu kola → asiaticoside
2 Crocetin
2 5-fluorouracil
2 Deguelin
2 Dandelion Root
2 Disulfiram
2 Ellagic acid
2 Fucoidan
2 Garcinol
2 Grapeseed extract
2 Naringin
2 Phenethyl isothiocyanate
2 Vitamin C (Ascorbic Acid)
2 Vitamin D3
2 VitK3,menadione
1 1,8-Cineole
1 Anthocyanins
1 Allicin (mainly Garlic)
1 alpha Linolenic acid
1 DTS(dibenzyl trisulphide) from Anamu
1 Aspirin
1 Baicalin
1 Berbamine
1 Biochanin A
1 Brucea javanica
1 Boron
1 Caffeic acid
1 Carnosic acid
1 Cucurbitacin
1 Radiotherapy/Radiation
1 Oxaliplatin
1 Dichloroacetate
1 Docosahexaenoic Acid
1 immunotherapy
1 Copper and Cu NanoParticles
1 Evodiamine
1 Eurycomanone
1 Cinnamon
1 Shilajit/Fulvic Acid
1 Gallic acid
1 Paclitaxel
1 Proanthocyanidins
1 Hydroxycinnamic-acid
1 Ivermectin
1 Sorafenib (brand name Nexavar)
1 Juglone
1 Licorice
1 Lactoferrin
1 methotrexate
1 Magnolol
1 Myricetin
1 Niclosamide (Niclocide)
1 Oleocanthal
1 Plumbagin
1 Psoralidin
1 isoflavones
1 Sanguinarine
1 α-Santalol/Sandalwood oil
1 Selenium
1 Selenate
1 Gemcitabine (Gemzar)
1 Selenite (Sodium)
1 statins
1 Citric Acid
1 Terpinen-4-ol / Tea Tree Oil
1 Thymol-Thymus vulgaris
1 Ursolic acid
1 Vitamin K2
1 Zinc
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:96  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page